เอกสารอ้างอิง
[1]. Shrander SP. Contraception. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiological approach. 10th ed. New York: McGraw-Hill Education; 2017:1251-53.
[2]. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13(3):177-89.
[3]. Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, Jamieson DJ. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;216(5): 489.e1-489.e7.
[4]. Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18(1):108.
[5]. Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain. 2013;14(1):66.
[6]. Edlow AG, Bartz D. Hormonal contraceptive options for women with headache: a review of the evidence. Rev Obstet Gynecol. 2010;3(2):55-65.
[7]. Ethinylestradiol and Cafergot. In: Lexi-drugs online [database on the Internet]. Hudson (OH): Lexicomp, Inc.; 2021 [cited 16 Nov 2021]. Available from: http://online.lexi.com. Subscription required to view.